- Home
- REBN vs BIVI Comparison
REBN vs BIVI Comparison
Compare REBN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- BIVI
- Stock Information
- Founded
- REBN 2015
- BIVI 2013
- Country
- REBN United States
- BIVI United States
- Employees
- REBN N/A
- BIVI N/A
- Industry
- REBN Restaurants
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- BIVI Health Care
- Exchange
- REBN Nasdaq
- BIVI Nasdaq
- Market Cap
- REBN 15.3M
- BIVI 14.2M
- IPO Year
- REBN 2022
- BIVI N/A
- Fundamental
- Price
- REBN $2.42
- BIVI $1.97
- Analyst Decision
- REBN
- BIVI
- Analyst Count
- REBN 0
- BIVI 0
- Target Price
- REBN N/A
- BIVI N/A
- AVG Volume (30 Days)
- REBN 77.7K
- BIVI 234.2K
- Earning Date
- REBN 11-18-2025
- BIVI 11-12-2025
- Dividend Yield
- REBN N/A
- BIVI N/A
- EPS Growth
- REBN N/A
- BIVI N/A
- EPS
- REBN N/A
- BIVI N/A
- Revenue
- REBN $6,565,623.00
- BIVI N/A
- Revenue This Year
- REBN $335.98
- BIVI N/A
- Revenue Next Year
- REBN N/A
- BIVI N/A
- P/E Ratio
- REBN N/A
- BIVI N/A
- Revenue Growth
- REBN 14.03
- BIVI N/A
- 52 Week Low
- REBN $1.03
- BIVI $1.42
- 52 Week High
- REBN $8.30
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- REBN N/A
- BIVI 48.39
- Support Level
- REBN N/A
- BIVI $1.86
- Resistance Level
- REBN N/A
- BIVI $2.04
- Average True Range (ATR)
- REBN 0.00
- BIVI 0.12
- MACD
- REBN 0.00
- BIVI 0.07
- Stochastic Oscillator
- REBN 0.00
- BIVI 81.23
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.